ClinicalTrials.gg
RecruitingNCT06989112DE-01Updated Nov 16, 2026

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

A Phase 3 interventional study of Trastuzumab deruxtecan and Rilvegostomig in Endometrial Cancer, sponsored by AstraZeneca. Recruiting at 256 sites in 23 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Nov 16, 2026Site recruiting status changed2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Endometrial Neoplasms by AstraZeneca — 9 open to participants now, 13 under way, 4 of them phase 3. Endometrial Neoplasms · AstraZeneca.

Planned enrollment
5th of 12
600 · median 457
Started
2025
with 6 others
Phase 3
4 of 17
2 open now
Primary completion
2029-01
later than 10 of 12 live
Registered
11th of 17
by date

Among the 17 studies in Endometrial Neoplasms by AstraZeneca, this one is the 5th largest by planned enrollment of the 12 interventional ones that give a count, is one of 7 that started in 2025, is one of 4 in phase 3, reaches primary completion later than 10 of the 12 other live ones, and was the 11th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

9 of the 17 studies in Endometrial Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Endometrial Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.

03

Conditions studied

  • Endometrial Cancer

Keywords

  • Endometrial Cancer
  • Uterine Cancer
  • Endometrial Carcinoma
  • Human epidermal growth factor receptor 2 (HER2)
  • pMMR
  • Trastuzumab deruxtecan
  • T-DXd
  • DS-8201a
  • Anti-HER2-Antibody Drug Conjugate(ADC)
  • DESTINY-Endometrial01
  • Programmed Cell Death-1 (PD1, PD-1)
  • Immune checkpoint inhibitor
  • TIGIT
  • Pembrolizumab
  • Carboplatin
  • Paclitaxel
  • Rilvegostomig
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • ≥ 18 years of age at the time of screening. Other age restrictions may apply as per local regulations.
  • confirmed diagnosis of epithelial endometrial carcinoma. All histologies are allowed except for sarcomas (carcinosarcomas are allowed).
  • Participant must have primary advanced disease (Stage III/IV) or recurrent endometrial cancer and meet at least one of the following criteria:

    1. Primary Stage III (per FIGO 2023) disease with at baseline per 1.1 based on the investigator's assessment.
    2. Primary Stage IV (per FIGO 2023) disease regardless of presence of measurable disease at baseline.
    3. Recurrent disease regardless of presence of measurable disease at baseline.
  • Endometrial cancer with IHC expression of 3+ or 2+ by prospective central testing.
  • Endometrial cancer that is determined pMMR by prospective central testing.
  • Provision of an adequate FFPE tumor tissue sample for central HER2, MMR, and IHC testing.
  • Prior therapy:

    1. No prior chemotherapy for the treatment of EC, except for one prior line of / neoadjuvant chemotherapy with curative intent (chemotherapy or chemoradiation) if completed ≥ 6 months prior to signature of the main ICF. Prior trastuzumab in the adjuvant/neoadjuvant setting is allowed.
    2. No prior exposure to antibody-drug conjugates or immune checkpoint inhibitors
    3. Participants may have received prior radiation therapy for the treatment of endometrial cancer. Adequate treatment is required
    4. Participants may have received prior hormonal therapy for the treatment of endometrial cancer. Adequate treatment washout period is required
  • 0-1.
  • ≥ 50% within 28 days before randomization.
  • Adequate organ and bone marrow function within 14 days before randomization.
  • The participant is not considered a candidate for curative therapy in the judgment of the investigator.

Key Exclusion Criteria:

  • Any severe or uncontrolled systemic diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or would jeopardize compliance with the protocol.
  • Active or ongoing serious chronic gastrointestinal conditions associated with diarrhea, primary immunodeficiency, or non-infectious skin disease requiring systemic treatment.
  • Active or prior documented or inflammatory disorders requiring chronic systemic treatment with the use of disease-modifying agents, , or drugs.
  • History of (non-infectious) ILD/pneumonitis that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
  • Lung criteria:

    1. Lung-specific intercurrent illnesses including, but not limited to, any underlying pulmonary disorder (e.g., pulmonary emboli within 3 months of the study enrollment, severe asthma, severe [COPD], restrictive lung disease, etc.).
    2. Any autoimmune, connective tissue or inflammatory disorders where there is documented, or a suspicion of pulmonary involvement at the time of screening.
    3. Prior pneumonectomy (complete).
  • History of myocardial infarction or unstable angina within 6 months before randomization, or symptomatic congestive heart failure ( Class II to IV), clinically significant arrhythmia, uncontrolled hypertension, cardiomyopathy of any etiology or history of myocarditis.
  • History of organ transplant or stem cell transplant.
  • Spinal cord compression or clinically active central nervous system . Participants with clinically inactive may be included in the study.
  • Evidence of any of the following infections:

    1. Active tuberculosis
    2. infection that is not well controlled.
    3. Active or C infection.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Arm A: T-DXd + Rilvegostomig

    T-DXd IV Q3W plus rilvegostomig IV Q3W. Treatment will continue until objective disease progression according to RECIST v1.1 as assessed by the Investigator and confirmed by BICR or until other discontinuation criteria is met, whichever occurs first.

    Drug: Trastuzumab deruxtecan · Drug: Rilvegostomig

  • Experimental
    Arm B: T-DXd + Pembrolizumab

    T-DXd IV Q3W plus pembrolizumab IV Q3W. Treatment will continue until objective disease progression according to RECIST v1.1 as assessed by the Investigator and confirmed by BICR or until other discontinuation criteria is met, whichever occurs first.

    Drug: Trastuzumab deruxtecan · Drug: Pembrolizumab

  • Active comparator
    Arm C: Carboplatin + Paclitaxel + Pembrolizumab

    Carboplatin, paclitaxel and pembrolizumab administered Q3W for 6 cycles, followed by maintenance with pembrolizumab IV Q6W for 14 cycles. Treatment with pembrolizumab will continue for up to 20 total cycles (approximately 24 months, accounting for combination and maintenance phases) or until other discontinuation criteria is met, whichever occurs first. At the discretion of the investigator, participants may continue to receive carboplatin, paclitaxel and pembrolizumab Q3W for up to 10 cycles. Docetaxel can be used as an alternative to paclitaxel for participants who had a hypersensitivity reaction to paclitaxel with a failed rechallenge (or not amenable to rechallenge), according to the investigator's clinical judgment.

    Drug: Pembrolizumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Docetaxel

Interventions

  • Experimental therapy by intravenous infusion

    Also known as: DS-8201a, T-DXd

  • Experimental therapy by intravenous infusion

  • Immunotherapy by intravenous infusion

    Also known as: Keytruda

  • Standard of Care (SoC) chemotherapy by intravenous infusion

    Also known as: Carbomedac, Carbosin, Paraplatin

  • Standard of Care (SoC) chemotherapy by intravenous infusion

    Also known as: Anzatax, Ebetaxel, Oncotaxel, Paclitax, Paclitaxin, Paxene, Taxol

  • Standard of Care (SoC) chemotherapy by intravenous infusion

    Also known as: Docirena, Taxceus, Taxotere

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS), as assessed by BICR

    Defined as time from randomization until progression per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR), or death due to any cause.

    Time frame: Until progression or death due to any cause (assessed up to approximately 45 months).

Secondary outcomes

  1. Overall Survival (OS)

    Defined as the time from randomization until the date of death due to any cause.

    Time frame: Until the date of death due to any cause (assessed up to approximately 70 months).

  2. Progression Free Survival (PFS) as assessed by the investigator

    PFS by investigator has the same attributes as estimand of PFS by BICR except tumor assessment is by the investigator.

    Time frame: Until progression or death due to any cause (assessed up to approximately 70 months).

  3. Time from randomization to second progression or death (PFS2)

    PFS2 will be defined as the time from randomization to the earliest of the progression event (following the initial investigator-assessed progression), after first subsequent therapy, or death.

    Time frame: Until the earliest of the progression event (following the initial investigator-assessed progression), after first subsequent therapy, or death (assessed up to approximately 70 months).

  4. Objective response rate (ORR), as assessed by BICR and investigator

    ORR as assessed and confirmed by BICR is defined as the proportion of participants who have a complete response (CR) or partial response (PR), as determined and confirmed by BICR. ORR as assessed and confirmed by the investigator has the same attributes as estimand of ORR by BICR except tumor assessment per the investigator.

    Time frame: Until progression or the starting of subsequent anticancer therapy (assessed up to approximately 45 months).

  5. Duration of response (DoR), as assessed by BICR and investigator

    DoR as assessed by BICR will be defined as the time from the date of first documented response of confirmed responders until date of documented progression per RECIST 1.1, or death due to any cause. DoR as assessed by the investigator has the same attributes as estimand of DoR by BICR except tumor assessment per the investigator.

    Time frame: Until progression or death due to any cause (assessed up to approximately 45 months).

  6. Safety and tolerability

    Safety and tolerability will be evaluated in terms of AEs/serious AEs (SAEs), AESI, vital signs, clinical safety laboratory assessments, ECG and ECHO/MUGA scan results.

    Time frame: Safety is assessed until the 90 days (+7) after the last dose (assessed up to approximately 70 months).

  7. Pharmacokinetics of T-DXd, total anti-HER2 antibody, DXd and rilvegostomig

    Serum concentration of T-DXd, total anti-HER2 antibody, DXd and rilvegostomig.

    Time frame: Up to safety follow-up period (assessed up to approximately 45 months).

  8. Immunogenicity of T- DXd and rilvegostomig

    Presence of ADAs for T-DXd or rilvegostomig.

    Time frame: Up to safety follow-up period (assessed up to approximately 45 months).

  9. Patient-reported tolerability

    Patient-reported tolerability will be described among participants, as treated, using the following outcomes: * Symptomatic AEs: Descriptive summary of the proportion of participants reporting symptomatic AEs while on treatment, as assessed by items from the EORTC Item Library and the FACT/GOG-NTX-4 * Overall side-effect bother: Descriptive summary of the proportion of participants reporting overall side-effect bother on the PGI-TT while on treatment

    Time frame: Until progression as assessed by BICR (assessed up to approximately 45 months).

  10. Progression-free survival (PFS) according to MMR status to determine the clinical utility of a MMR diagnostic test

    PFS is defined as time from randomization until progression per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) as assessed by BICR, or death due to any cause.

    Time frame: Through completion of study, assessed up to approximately 70 months.

  11. Overall survival (OS) according to MMR status to determine the clinical utility of a MMR diagnostic test

    OS defined as the time from randomization until the date of death due to any cause.

    Time frame: Through completion of study, assessed up to approximately 70 months.

  12. Progression-free survival (PFS) according to HER2 expression to determine the clinical utility of a HER2 diagnostic test

    PFS is defined as time from randomization until progression per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) as assessed by BICR, or death due to any cause.

    Time frame: Through completion of study, assessed up to approximately 70 months.

  13. Overall survival (OS) according to HER2 expression to determine the clinical utility of a HER2 diagnostic test

    OS is defined as the time from randomization until the date of death due to any cause.

    Time frame: Through completion of study, assessed up to approximately 70 months.

07

Study locations

208 of 256 sites recruiting
  • Research Site
    Tucson, Arizona 85704, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Little Rock, Arkansas 72205, United States
    Recruiting
  • Research Site
    Duarte, California 91010, United States
    Recruiting
  • Research Site
    Irvine, California 92618, United States
    Recruiting
  • Research Site
    La Jolla, California 92037, United States
    Recruiting
  • Research Site
    Palo Alto, California 94304, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    San Francisco, California 94143, United States
    Not yet recruiting
  • Research Site
    Sylmar, California 91342, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Fort Myers, Florida 33901, United States
    Recruiting
  • Research Site
    Miami, Florida 33133, United States
    Not yet recruiting
  • Research Site
    Miami Beach, Florida 33140, United States
    Recruiting
  • Research Site
    Orlando, Florida 32804, United States
    Recruiting
  • Research Site
    St. Petersburg, Florida 33705, United States
    Recruiting
  • Research Site
    Tampa, Florida 33612, United States
    Recruiting
  • Research Site
    West Palm Beach, Florida 33401, United States
    Recruiting
  • Research Site
    Augusta, Georgia 30912, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Honolulu, Hawaii 96813, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Arlington Heights, Illinois 60005, United States
    Recruiting
  • Research Site
    Evanston, Illinois 60201, United States
    Recruiting
  • Research Site
    Shreveport, Louisiana 71103, United States
    Recruiting
  • Research Site
    Baltimore, Maryland 21201, United States
    Recruiting
  • Research Site
    Silver Spring, Maryland 20910, United States
    Not yet recruiting
  • Research Site
    Boston, Massachusetts 02111, United States
    Recruiting
  • Research Site
    Worcester, Massachusetts 01655, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Research Site
    Detroit, Michigan 48201, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Marshall, Minnesota 56258, United States
    Recruiting
  • Research Site
    Minneapolis, Minnesota 55455, United States
    Recruiting
  • Research Site
    Rochester, Minnesota 55905, United States
    Recruiting
  • Research Site
    Jackson, Mississippi 39216, United States
    Recruiting
  • Research Site
    Springfield, Missouri 65804, United States
    Recruiting
  • Research Site
    St Louis, Missouri 63141, United States
    Recruiting
  • Research Site
    Las Vegas, Nevada 89169, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Lebanon, New Hampshire 03756, United States
    Recruiting
  • Research Site
    Hackensack, New Jersey 07601, United States
    Recruiting
  • Research Site
    Albuquerque, New Mexico 87109, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    New York, New York 10016, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    New York, New York 10065, United States
    Recruiting
  • Research Site
    New York, New York 10075, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Charlotte, North Carolina 28204, United States
    Recruiting
  • Research Site
    Winston-Salem, North Carolina 27103, United States
    Recruiting
  • Research Site
    Winston-Salem, North Carolina 27157, United States
    Recruiting
  • Research Site
    Cincinnati, Ohio 45220, United States
    Recruiting
  • Research Site
    Columbus, Ohio 43210, United States
    Recruiting
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
    Not yet recruiting
  • Research Site
    Tulsa, Oklahoma 74134, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Eugene, Oregon 97401, United States
    Recruiting
  • Research Site
    Abington, Pennsylvania 19001, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Hershey, Pennsylvania 17033, United States
    Not yet recruiting
  • Research Site
    Philadelphia, Pennsylvania 19111, United States
    Recruiting
  • Research Site
    Pittsburgh, Pennsylvania 15224, United States
    Recruiting
  • Research Site
    Providence, Rhode Island 02905, United States
    Recruiting
  • Research Site
    Charleston, South Carolina 29425, United States
    Recruiting
  • Research Site
    Sioux Falls, South Dakota 57105, United States
    Recruiting
  • Research Site
    Austin, Texas 78758, United States
    Recruiting
  • Research Site
    Fort Worth, Texas 76104, United States
    Recruiting
  • Research Site
    Houston, Texas 77030, United States
    Recruiting
  • Research Site
    San Antonio, Texas 78240, United States
    Recruiting
  • Research Site
    Charlottesville, Virginia 22908, United States
    Recruiting
  • Research Site
    Fairfax, Virginia 22031, United States
    Recruiting
  • Research Site
    Seattle, Washington 98133, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Madison, Wisconsin 53792, United States
    Recruiting
  • Research Site
    Blacktown, 2148, Australia
    Recruiting
  • Research Site
    East Melbourne, 3002, Australia
    Terminated

    Not enrolling at this site — choose another above.

  • Research Site
    Nedlands, 6009, Australia
    Recruiting
  • Research Site
    South Brisbane, 4101, Australia
    Recruiting
  • Research Site
    Innsbruck, 6020, Austria
    Not yet recruiting
  • Research Site
    Linz, 4021, Austria
    Not yet recruiting
  • Research Site
    Vienna, 1090, Austria
    Not yet recruiting
  • Research Site
    Wein, 1130, Austria
    Recruiting
  • Research Site
    Anderlecht, 1070, Belgium
    Recruiting
  • Research Site
    Brussels, 1200, Belgium
    Recruiting
  • Research Site
    Charleroi, 6060, Belgium
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Ghent, 9000, Belgium
    Recruiting
  • Research Site
    Leuven, 3000, Belgium
    Recruiting
  • Research Site
    Liège, 4000, Belgium
    Recruiting
  • Research Site
    Barretos, 14784-057, Brazil
    Recruiting
  • Research Site
    Belo Horizonte, 30130 100, Brazil
    Recruiting
  • Research Site
    Goiânia, 74000-000, Brazil
    Recruiting
  • Research Site
    Londrina, 86015-520, Brazil
    Recruiting
  • Research Site
    Porto Alegre, 90020-090, Brazil
    Recruiting
  • Research Site
    Porto Alegre, 90610000, Brazil
    Recruiting
  • Research Site
    Rio de Janeiro, 20220-410, Brazil
    Recruiting
  • Research Site
    Salvador, 41.950-610, Brazil
    Recruiting
  • Research Site
    São Paulo, 01246-000, Brazil
    Recruiting
  • Research Site
    São Paulo, 01317-001, Brazil
    Recruiting
  • Research Site
    São Paulo, 1409, Brazil
    Recruiting
  • Research Site
    Teresina, 64049-200, Brazil
    Recruiting
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
    Recruiting
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
    Recruiting
  • Research Site
    Winnipeg, Manitoba R3E 0V9, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Halifax, Nova Scotia B3H 2Y9, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    London, Ontario N6A 4L6, Canada
    Recruiting
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
    Recruiting
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
  • Research Site
    Montreal, Quebec H1T 2M4, Canada
    Recruiting
  • Research Site
    Montreal, Quebec H2X 0A9, Canada
    Recruiting
  • Research Site
    Montreal, Quebec H3G 1A4, Canada
    Recruiting
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
    Not yet recruiting
  • Research Site
    Québec, Quebec G1J 1Z4, Canada
    Recruiting

Showing the first 100 of 256 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jan 2029, 45 months after the start.

Of 44 phase 3 interventional studies under Endometrial Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 126. This study's planned 45 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
May 25, 2025
StartActual
Mar 27, 2025
Primary completionEst.
Jan 19, 2029
CompletionEst.
Feb 19, 2031
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed. 12 sites changed recruiting status (7 now recruiting, 3 now withdrawn, …)
Show 12 sites
  • Research Site · San Francisco, United StatesWithdrawn→Not yet recruiting
  • Research Site · Marshall, United StatesNot yet recruiting→Recruiting
  • Research Site · Albuquerque, United StatesSuspended→Withdrawn
  • Research Site · Lanzhou, ChinaRecruiting→Withdrawn
  • Research Site · Essen, GermanyNot yet recruiting→Recruiting
  • Research Site · Hamburg, GermanyNot yet recruiting→Recruiting
  • Research Site · Orlando, United StatesNot yet recruiting→Recruiting
  • Research Site · Winston-Salem, United StatesNot yet recruiting→Recruiting
  • Research Site · East Melbourne, AustraliaRecruiting→Terminated
  • Research Site · Saint-Herblain, FranceSuspended→Withdrawn
  • Research Site · Kassel, GermanyNot yet recruiting→Recruiting
  • Research Site · Yokohama, JapanNot yet recruiting→Recruiting
Show 2 added (1 United States, 1 Canada)
  • Research Site · Hershey, United States
  • Research Site · Montreal, Canada
Show 1 removed
  • Research Site · Charlotte, United States
across 2 updates, Oct 13, 2026 – Nov 16, 2026
Show all 2 updates
  1. Nov 16, 2026
    1 site removed. 6 sites changed recruiting status (4 now recruiting, 1 now terminated, …)
    Show 6 sites
    • Research Site · Orlando, United StatesNot yet recruiting→Recruiting
    • Research Site · Winston-Salem, United StatesNot yet recruiting→Recruiting
    • Research Site · East Melbourne, AustraliaRecruiting→Terminated
    • Research Site · Saint-Herblain, FranceSuspended→Withdrawn
    • Research Site · Kassel, GermanyNot yet recruiting→Recruiting
    • Research Site · Yokohama, JapanNot yet recruiting→Recruiting
    Show 1 removed
    • Research Site · Charlotte, United States
    + 1 other change: verification date
  2. Oct 13, 2026
    2 sites added. 6 sites changed recruiting status (3 now recruiting, 2 now withdrawn, …)
    Show 6 sites
    • Research Site · San Francisco, United StatesWithdrawn→Not yet recruiting
    • Research Site · Marshall, United StatesNot yet recruiting→Recruiting
    • Research Site · Albuquerque, United StatesSuspended→Withdrawn
    • Research Site · Lanzhou, ChinaRecruiting→Withdrawn
    • Research Site · Essen, GermanyNot yet recruiting→Recruiting
    • Research Site · Hamburg, GermanyNot yet recruiting→Recruiting
    Show 2 added (1 United States, 1 Canada)
    • Research Site · Hershey, United States
    • Research Site · Montreal, Canada
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06989112
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo Co., Ltd., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Responsible party
Sponsor
First posted
May 25, 2025
Start date
Mar 27, 2025
Primary completion
Jan 19, 2029 (estimated)
Completion
Feb 19, 2031 (estimated)
Last update
Nov 16, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab deruxtecan · Rilvegostomig

Start the discussion